# Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

> **NCT03556956** · PHASE2,PHASE3 · COMPLETED · sponsor: **AB Science** · enrollment: 219 (actual)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Masitinib

## Key facts

- **NCT ID:** NCT03556956
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03556956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03556956, "Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03556956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*